IDEXX Laboratories Forecast, price target & analysts
IDEXX Laboratories Target price 2025 - Analyst rating & recommendation
IDEXX Laboratories Classifications & Recommendation:
IDEXX Laboratories Price Target
| Target Price | $527.00 |
| Price | $441.03 |
| Potential | 19.49% |
| Number of Estimates | 11 |
| 11 Analysts have issued a price target IDEXX Laboratories 2026 . The average IDEXX Laboratories target price is $527.00. This is 19.49% higher than the current stock price. The highest price target is $566.00 28.34% , the lowest is $460.00 4.30% . | |
| A rating was issued by 16 analysts: 9 Analysts recommend IDEXX Laboratories to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2026 of 19.49% . Most analysts recommend the IDEXX Laboratories stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2028
11 Analysts have issued a sales forecast IDEXX Laboratories 2025 . The average IDEXX Laboratories sales estimate is $4.1b . This is 5.63% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.2b 6.81% , the lowest is $4.1b 4.97% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $3.9b | 6.46% |
|---|---|---|
| 2025 | $4.1b | 5.63% |
| 2026 | $4.4b | 7.86% |
| 2027 | $4.8b | 8.87% |
| 2028 | $5.2b | 8.18% |
8 Analysts have issued an IDEXX Laboratories EBITDA forecast 2025. The average IDEXX Laboratories EBITDA estimate is $1.4b . This is 14.23% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.6b 23.96% , the lowest is $1.4b 9.91% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $1.3b | 4.11% |
|---|---|---|
| 2025 | $1.4b | 14.26% |
| 2026 | $1.6b | 9.57% |
| 2027 | $1.7b | 8.12% |
| 2028 | $1.9b | 9.16% |
EBITDA Margin
| 2024 | 32.25% | 2.21% |
|---|---|---|
| 2025 | 34.89% | 8.18% |
| 2026 | 35.44% | 1.58% |
| 2027 | 35.19% | 0.71% |
| 2028 | 35.51% | 0.91% |
12 IDEXX Laboratories Analysts have issued a net profit forecast 2025. The average IDEXX Laboratories net profit estimate is $977m . This is 12.25% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $989m 13.59% , the lowest is $965m 10.87% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $871m | 6.06% |
|---|---|---|
| 2025 | $977m | 12.25% |
| 2026 | $1.1b | 13.32% |
| 2027 | $1.3b | 13.54% |
| 2028 | $1.4b | 13.23% |
Net Margin
| 2024 | 22.34% | 0.37% |
|---|---|---|
| 2025 | 23.74% | 6.27% |
| 2026 | 24.94% | 5.05% |
| 2027 | 26.01% | 4.29% |
| 2028 | 27.23% | 4.69% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
12 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $11.98 . This is 12.28% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $12.12 13.59% , the lowest is $11.83 10.87% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $10.67 | 6.06% |
|---|---|---|
| 2025 | $11.98 | 12.28% |
| 2026 | $13.57 | 13.27% |
| 2027 | $15.41 | 13.56% |
| 2028 | $17.45 | 13.24% |
P/E ratio
| Current | 41.35 | 27.77% |
|---|---|---|
| 2025 | 36.82 | 10.96% |
| 2026 | 32.49 | 11.76% |
| 2027 | 28.62 | 11.91% |
| 2028 | 25.27 | 11.71% |
Based on analysts' sales estimates for 2025, the IDEXX Laboratories stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 8.88 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 8.71 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 9.38 | 29.15% |
|---|---|---|
| 2025 | 8.88 | 5.31% |
| 2026 | 8.23 | 7.29% |
| 2027 | 7.56 | 8.15% |
| 2028 | 6.99 | 7.56% |
P/S ratio
| Current | 9.20 | 29.61% |
|---|---|---|
| 2025 | 8.71 | 5.33% |
| 2026 | 8.08 | 7.29% |
| 2027 | 7.42 | 8.15% |
| 2028 | 6.86 | 7.56% |
IDEXX Laboratories...
Current IDEXX Laboratories Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler | Neutral ➜ Neutral | Unchanged | Feb 10 2025 |
| B of A Securities | Neutral ➜ Neutral | Unchanged | Feb 04 2025 |
| Barclays | Overweight ➜ Overweight | Unchanged | Feb 04 2025 |
| Morgan Stanley | Overweight ➜ Overweight | Unchanged | Jan 29 2025 |
| Leerink Partners | Outperform | Initiated | Dec 02 2024 |
| Barclays | Overweight ➜ Overweight | Unchanged | Nov 04 2024 |
| Piper Sandler | Neutral ➜ Neutral | Unchanged | Nov 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Piper Sandler: Neutral ➜ Neutral
|
Feb 10 2025 |
|
Unchanged
B of A Securities: Neutral ➜ Neutral
|
Feb 04 2025 |
|
Unchanged
Barclays: Overweight ➜ Overweight
|
Feb 04 2025 |
|
Unchanged
Morgan Stanley: Overweight ➜ Overweight
|
Jan 29 2025 |
|
Initiated
Leerink Partners: Outperform
|
Dec 02 2024 |
|
Unchanged
Barclays: Overweight ➜ Overweight
|
Nov 04 2024 |
|
Unchanged
Piper Sandler: Neutral ➜ Neutral
|
Nov 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
